Navigation Links
Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP
Date:2/14/2011

Partnering to Fight TB: The Role of a TB Vaccine PDP
An Exhibitor's Workshop at the 2011 AAAS Annual Meeting

DATE: SUNDAY, FEBRUARY 20, 1:00-2:00 PM

VENUE: 2011 AAAS ANNUAL MEETING, WASHINGTON CONVENTION CENTER, ROOM 158AB

Speakers at the workshop will provide an overview of the state of the global TB epidemic and efforts to develop TB vaccines; the role of non-profit product development partnerships such as Aeras; and ways that scientists and researchers can add their voices to a global call for action on TB.

SPEAKERS:

  • Lewellys F. Barker, MD, Senior Medical Advisor, Aeras
  • David Bryden, Senior Program Policy Officer at the Infectious Diseases Society of America's Center for Global Health Policy
  • Claire Wingfield, TB/HIV Project Coordinator at the Treatment Action Group

BACKGROUND:

TB is one of the world's deadliest infectious diseases, killing nearly 2 million men, women and children every year. Despite global efforts to prevent and treat TB, the epidemic is becoming more complex and difficult to diagnose and treat due in large part to the emergence of drug-resistant forms of TB and the emergence of the HIV epidemic. TB is responsible for the majority of AIDS deaths in Africa. The currently available vaccine, BCG, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. New TB vaccines are urgently needed as part of a comprehensive effort to stop TB.


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras Global TB Vaccine Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. October 2008 GEOLOGY and GSA TODAY media highlights
2. Mediator in communication between neurons and muscle cells found
3. December 2008 Geology and GSA Today media highlights
4. December Geosphere media highlights
5. January GEOLOGY media highlights
6. January-February GSA Bulletin media highlights
7. BIO-key(R) Fingerprint Biometrics Media Spotlights
8. February 2009 Geology and GSA Today media highlights
9. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
10. Mass media often failing in its coverage of global warming, says climate researcher
11. Patience pays off with methanol for uranium bioremediation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Oregon (PRWEB) , ... December 08, 2016 , ... ... and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI ... not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... bioprocess media products engineered to radically streamline culture processes, minimize processing time, ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented today ... clinical trial for its lead drug candidate, AC0010, at the World Conference on ... to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 ...
Breaking Biology Technology: